trending Market Intelligence /marketintelligence/en/news-insights/trending/KC2Ya9o8dHMYafBiMXKLZw2 content esgSubNav
In This List

AstraZeneca oncology head to join Innate Pharma

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


AstraZeneca oncology head to join Innate Pharma

AstraZeneca PLC's head of oncology is joining Innate Pharma SA.

The company appointed Mondher Mahjoubi as chairman of the executive board, replacing Hervé Brailly, who has been appointed the chairman of the Innate Pharma supervisory board.

Innate Pharma's existing supervisory board chairman, Gilles Brisson, is stepping down but will remain on the board. Meanwhile, Philippe Pouletty is resigning from the Innate Pharma supervisory board, and Catherine Moukheibir is stepping down from the executive board.

Mahjoubi is the senior vice president of therapeutic area head-oncology and global product and portfolio strategy at AstraZeneca. Brailly is the co-founder and CEO of Innate Pharma.

The moves are effective Dec. 30 and are aimed at "driving the company strategy towards late-stage development."

Elsewhere, Laure-Hélène Mercier was appointed Innate Pharma's CFO after serving as the company's executive vice president of finance.